Evidence map›Paper›PMID 38013490›Full record

ArticleCancer biology & medicine2023

Single-arm trials for domestic oncology drug approvals in China.

Hong Zhang, Sen Liu, Chenghao Ge, Xiaozhen Liu, Yang Liu, Chen Yin, Yi Li, Jing An, Zhongtian Yan, Xiaoyuan Chen

Abstract readEditorial
In one paragraph

Article in Cancer biology & medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hong Zhang *Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China.
Sen Liu *Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing 100084, China.
Chenghao GeTsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing 100084, China.
Xiaozhen LiuTsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing 100084, China.
Yang LiuTsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing 100084, China.
Chen YinTsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing 100084, China.
Yi LiTsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing 100084, China.
Jing AnTsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing 100084, China.
Zhongtian YanTsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing 100084, China.
Xiaoyuan ChenTsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing 100084, China.ORCID 0000-0002-3379-3444

Funding

China Society for Drug Regulation 2023-Y-Y-002
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsDrug ApprovalChinaHumansMedical OncologyAntineoplastic Agents

Identifiers

PMID38013490
PMCPMC10690876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.